Choose your preferred way to stay informed of new case launches and settlement deadlines
The filed complaint alleges that Telix Pharmaceuticals Limited made materially false and/or misleading statements and/or failed to disclose that: On April 28, 2025, Telix issued a press release announcing that the FDA issued a Complete Response Letter denying approval of Telix’s New Drug Application for TLX101-CDx (“Pixclara”). The FDA indicated “additional confirmatory clinical evidence is required to progress the application.” Following this news, Telix’s stock price fell by $1.47 per share to open at $17.33 per share.
In order to be eligible to join the TLX class action lawsuit, you must have incurred a loss on shares of Telix Pharmaceuticals Limited purchased during the class period listed above.
TOP
